On Oct. 30, 2020, Hologic announced that it had been awarded a $119 million contract from the U.S. government to expand its production capacity for COVID-19 molecular tests. The contract supported capital and labor investments enabling Hologic to provide 13 million COVID-19 tests per month for the U.S. market by January of 2022.